Patent classifications
C07D235/24
MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
- Mark Thomas Miller ,
- Corey Anderson ,
- Vijayalaksmi Arumugam ,
- Brian Richard Bear ,
- Hayley Marie Binch ,
- Jeremy J. Clemens ,
- Thomas Cleveland ,
- Erica Conroy ,
- Timothy Richard Coon ,
- Bryan A. Frieman ,
- Peter Diederik Jan Grootenhuis ,
- Raymond Stanley Gross ,
- Sara Sabina Hadida-Ruah ,
- Haripada Khatuya ,
- Pramod Virupax Joshi ,
- Paul John Krenitsky ,
- Chun-Chieh Lin ,
- Gulin Erdogan Marelius ,
- Vito Melillo ,
- Jason McCartney ,
- Georgia McGaughey Nicholls ,
- Fabrice Jean Denis Pierre ,
- Alina Silina ,
- Andreas P. Termin ,
- Johnny Uy ,
- Jinglan Zhou
The present invention features a compound of formula I:
##STR00001##
or a pharmaceutically acceptable salt thereof, where R.sub.1, R.sub.2, R.sub.3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
METHOD FOR MONITORING FLUORESCENT POLYMER ANTISCALANTS IN INDUSTRIAL WATER SYSTEMS
The present invention relates to a fluorescently-tagged (co)polymer and use thereof useful as a scale inhibitor in industrial water systems. Said (co)polymer comprises a (i) reactive fluorescent compound selected from a benzodiazole compound (ii) at least one monoethylenically unsaturated acid monomer, and (iii) optionally, at least one monoethylenically unsaturated acid-free monomer.
Benzodiazepine derivatives as RSV inhibitors
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001##
which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
MIF MODULATORS
The invention provides novel heterocyclic compounds, pharmaceutical compositions and methods of treatment that modulate levels of MIF expression and treat disorders associated with high or low levels of MIF expression.
MIF MODULATORS
The invention provides novel heterocyclic compounds, pharmaceutical compositions and methods of treatment that modulate levels of MIF expression and treat disorders associated with high or low levels of MIF expression.
Benzoimidazoles as prolyl hydroxylase inhibitors
The present invention is directed to benzoimidazole compounds of the formula: ##STR00001##
and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
Benzoimidazoles as prolyl hydroxylase inhibitors
The present invention is directed to benzoimidazole compounds of the formula: ##STR00001##
and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
CARBOXYLIC ACID, ACYL SULFONAMIDE AND ACYL SULFAMIDE-DERIVATIZED BICYCLIC AZA-HETEROAROMATICS AS SELECTIVE MCL-1 INHIBITORS AND AS DUAL MCL-1/BCL-2 INHIBITORS
Mcl-1 selective inhibitors, Bcl-2 selective inhibitors, and Mcl-1/Bcl-2 dual inhibitors and methods of using the same for the treatment of disease are disclosed.
CARBOXYLIC ACID, ACYL SULFONAMIDE AND ACYL SULFAMIDE-DERIVATIZED BICYCLIC AZA-HETEROAROMATICS AS SELECTIVE MCL-1 INHIBITORS AND AS DUAL MCL-1/BCL-2 INHIBITORS
Mcl-1 selective inhibitors, Bcl-2 selective inhibitors, and Mcl-1/Bcl-2 dual inhibitors and methods of using the same for the treatment of disease are disclosed.
COMPOUNDS, COMPOSITIONS AND METHODS OF USE
Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.